Advances in the treatment of pulmonary tuberculosis

Journal of Thoracic Disease

Volumn 4, Issue 6, 2012, Pages 617-623

  Zhang, Xia ^a   Guo, Jing ^a  

^a NANJING CHEST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ARABINOGALACTAN; AZITHROMYCIN; BCG VACCINE; CAPREOMYCIN; CHLORPROMAZINE; CLARITHROMYCIN; CYCLOSERINE; DELAMANID; ECONAZOLE; ERYTHROMYCIN; GENTAMICIN; ISEPAMICIN; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; PAROMOMYCIN; PHENAZINE; PNU 172576; PNU 176665; PYRAZINOIC ACID; QUINOLONE; RIFAMYCIN; ROXITHROMYCIN; STREPTOMYCIN; SUTEZOLID; THIORIDAZINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTIFICIAL EMBOLISM; BRONCHIAL ARTERY EMBOLIZATION; BRONCHOSCOPY; CELL WALL; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; LUNG BIOPSY; LUNG TUBERCULOSIS; NONHUMAN; PULMONARY ARTERY EMBOLIZATION; REVIEW;

EID: 84873680927     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.10.10     Document Type: Review

References (65)

1. Wang J, Zhang HB, Zhou J.P., et al. Advances in new anti-tuberculosis targets and related drugs. Zhong Guo Yao Ke Da Xue Xue Bao 2012; 43: 1-8.
2. Gupta R, Lavollay M, Mainardi J.L., et al. The Mycobacterium tuberculosis protein Ldt Mt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat Med 2010; 16: 466-9.
3. Feng Z, Barletta RG Roles of Mycobacterium smegmatis D-alanine: D-alanine ligase and D-alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine. Antimicrob Agents Chemother 2003; 47: 283-91.
4. Qu H, Xin Y, Dong X., et al. An rmlA gene encoding d-glucose-1 -phosphate thymidylyltransferase is essential for mycobacterial growth. FEMS Microbiol Lett 2007; 275: 237-43.
5. Ma Y, Pan F, McNeil M. Formation of dTDP-rhamnose is essential for growth of mycobacteria. J Bacteriol 2002; 184: 3392-5.
6. Amin AG, Goude R, Shi L., et al. Emb A is an essential arabinosyltransferase in Mycobacterium tuberculosis. Microbiology 2008; 154: 240-8.
7. Huang H, Scherman MS, D'Haeze W, et al Identification and active expression of the Mycobacterium tuberculosis gene encoding 5-phospho-{alpha}-d- ribose-1-diphosphate: decaprenyl-phosphate 5-phosphoribosyltransferase, the first enzyme committed to decaprenylphosphoryl-d-arabinose synthesis. J Biol Chem 2005; 280: 24539-43.
8. Alderwick LJ, Molle V, Kremer L., et al. Molecular structure of Emb R, a response element of Ser/Thr kinase signaling in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2006; 103: 2558-63.
9. Qu H, Xin Y, Dong X., et al. An rmlA gene encoding d-glucose-1 -phosphate thymidylyltransferase is essential for mycobacterial growth. FEMS Microbiol Lett 2007; 275: 237-43.
10. Ma Y, Pan F, McNeil M. Formation of dTDP-rhamnose is essential for growth of mycobacteria. J Bacteriol 2002; 184: 3392-5.
11. Alderwick LJ, Seidel M, Sahm H., et al. Identification of a novel arabin of uranosyltransferase(Aft A) involved in cell wall arabinan biosynthesis in Mycobacteriumtuberculosis. J Biol Chem 2006; 281: 15653-61.
12. Sidel M, Alderwick KJ, Birch HJ Identification of a novel arabinofuranosyltranferase Alt B involved in a terminal step of cell wall arabinan biosynthesis in corymebacterianeae, such as corynebacterium glutamicum and Mycobacterium tuberculos. Bio Chem 2007; 282: 14729-40.
13. Seidel M, Alderwick LJ, Birch H.L., et al. Identification of a novel arabinofuranosyltransferase Aft B involved in a terminal step of cell wall arabinan biosynthesis in Corynebacterianeae, such as Corynebacterium glutamicum and Mycobacterium tuberculosis. J Biol Chem 2007; 282: 14729-40.
14. Birch HL, Alderwick LJ, Bhatt A, et al. Biosynthesis of mycobacterial arabinogalactan: identification of a novel alpha(1→3) arabinofuranosyltransferase. Mol Microbiol 2008; 69: 1191-206.
15. McLean KJ, Marshall KR, Richmond A, et al Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes. Microbiology 2002; 148: 2937-49.
16. Jackson CJ, Lamb DC, Kelly D.E., et al. Bactericidal and inhibitory effects of azole antifungal compounds on Mycobacterium smegmatis. FEMS Microbiol Lett 2000; 192: 159-62.
17. Ahmad Z, Sharma S, Khuller GK Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett 2006; 261: 181-6.
18. Ahmad Z, Sharma S, Khuller G.K., et al. Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis. Int J Antimicrob Agents 2006; 28: 543-4.
19. Ahmad Z, Sharma S, Khuller GK Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomedicine 2007; 3: 239-43.
20. Ahmad Z, Pandey R, Sharma S., et al. Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanopartides. Int J Antimicrob Agents 2008; 31: 142-6.
21. Lee SH, Kim S, Yun M.H., et al. Synthesis and antitubercular activity of monocyclic nitroimidazoles: insights from econazole. Bioorg Med Chem Lett 2011; 21: 1515-8.
22. Lounis N, Ji B, Truffot-Pernot C, et al. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother 1997; 41: 607-10.
23. Kanyok TP, Reddy MV, Chinnaswamy J, et al. In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains. Antimicrob Agents Chemother 1994; 38: 170-3.
24. Tang SJ, Xiao HP, Zhang Q. Research development on chemotherapy of multidrug-resistant tuberculosis. Zhong Hua Jie He He Hu Xi Za Zhi 2009, 32: 617-620.
25. Cremades R, Rodriguez JC, Garcia-Pachón E, et al. Interaction between linezolid and Mycobacterium tuberculosis in an experimental in vitro model. APMIS 2011; 119: 304-8.
26. Shandil RK, Jayaram R, Kaur P., et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007; 51: 576-82.
27. Nijland HM, Ruslami R, Suroto A.J., et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007; 45: 1001-7.
28. Coyne KM, Pozniak AL, Lamorde M, et al. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009; 23: 437-46.
29. de Jonge M.R., Koymans LH, Guillemont J.E., et al. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins 2007; 67: 971-80.
30. Toyota E, Kobayashi N, Takahara M., et al. Clinical investigation on endobronchial tuberculosis. Kekkaku. 1999; 74: 347-51.
31. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 40: 327-41.
32. Shandil RK, Jayaram R, Kaur P., et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007; 51: 576-82.
33. Nijland HM, Ruslami R, Suroto A.J., et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007; 45: 1001-7.
34. Amaral L, Viveiros M. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int J Antimicrob Agents 2012; 39: 376-80.
35. Mehta J, Gandhi IS, Sane S.B., et al. Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Lepr Rev 1986; 57: 67-76.
36. Zimic M, Fuentes P, Gilman R.H., et al. Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance. Tuberculosis (Edinburgh, Scotland) 2012; 92: 84-91.
37. Shi W, Zhang X, Jiang X., et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 2011; 333: 1630-2.
38. Diacon AH, Pyra A, Grobusch M., et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-405.
39. de Jonge M.R., Koymans LH, Guillemont J.E., et al. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins 2007; 67: 971-80.
40. Ding WM, Wang JP, Fu Y, et al. The clinical value of balloon dilatation through flexible bronchoscope in the management of tracheobronchial stenosis in 149 cases of endobronchial tuberculosis. Jie He Bing Yu Xiong Bu Zhong Liu 2010; 39: 250-5.
41. Li Y, Yao XP, Li H, et al. Therapeutic efficacy analysis of bronchoscopic interventional therapy on severe tuberculous main bronchial stenosis complicated with unilateral atelectasis. Zhong Hua Jie He He Hu Xi Za Zhi 2011; 34: 454-8.
42. Tang SJ, Xiao HP, Li Hong, et al. The short-term and long-term clinical treatment outcome of CT-guided percutaneous lung centesis administration in treatment of cavernous multi-drug resistant pulmonary tuberculosis. Zhong Guo Fang Lao Za Zhi 2009; 31: 40-5.
43. Zheng Z, Yang KY, Wang Y.L., et al. Clinical study of interventional treatment under CT-guided percutaneous lung centesis indwelling central venous catheter administration in treatment of cavitary multi-drug resistant pulmonary tuberculosis. Zhong Guo Dang Dai Yi Yao 2010; 21: 15-7.
44. Li XP, Wu JF, Bai Y, et al. Surgical operation in the treatment of 217 cases of pulmonary tuberculosis with cavitation. Lin Chuang Fei Ke Za Zhi 2011; 16: 84-5.
45. Uhlin M, Andersson J, Zumla A., et al. Adjunct immunotherapies for tuberculosis. J Infect Dis 2012; 205: 5325-34.
46. Dawson R, Condos R, Tse D., et al. Immunomodulation with recombinant interferon-gammalb in pulmonary tuberculosis. Plo S One 2009; 4:e6984.
47. Nandi B, Behar SM Regulation of neutrophils by interferon-gamma limits lung inflammation during tuberculosis infection. J Exp Med 2011; 208: 2251-62.
48. Shehata N, Palda VA, Meyer R.M., et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev 2010; 24: S7-27.
49. Nimmerjahn F, Ravetch JV Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513-33.
50. Ballow M. The Ig G molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011; 127: 315-23;qurz 24-25.
51. Lei JP, Xiong GL, Hu Q.F., et al. Immunotherapeutic efficacy of BCG vaccine in pulmonary tuberculosis and its preventive effect on multidrug-resistant tuberculosis. Zhong Hua Yu Fang Yi Xue Za Zhi 2008; 42: 86-9.
52. Lei JP, Peng YX, Guo L, et al. The different influence of BCG vaccination to the treatment effect of rats with tuberculosis and to the peripheral blood T lymphocyte subset at different period. Zhong Guo Fang Lao Za Zhi 2006; 28: 404-407.
53. Hu JG, Hu XW The effect of anti-tuberculosis drug combined with utilin's on pulmonary tuberculosis. Ji Bing Kong Zhi Za Zhi 2003; 7: 37-9.
54. Xu M, Chen BW, Shen X.B., et al. The immune modulatory function of M.smegmatis preparation in animals with different immune status. Zhong Hua Wei Sheng Wu He Mian Yi Xue Za Zhi 2005; 25:752-S.
55. Wang Q, Zhang J, Huang S.P., et al. Immunogenicity of the recombinant M.smegmatis expressing Ag85B-ESAT-6 fusion protein of M.tuberculosis in mice. Zhong Guo Yao Fang 2008; 19: 838-841.
56. Song MJ, Wang LM, Zhang X.L., et al. Immunotherapeutic effect of polysaccharide nuleic acid fraction of BCG on retreated pulmonary tuberculosis. Lin Chuang Fei Ke Za Zhi 2008; 13: 442-3.
57. Wang P, Wang LM, Zhang W, et al. Immunogenicity of the recombinant M.smegmatis expressing Ag85B-ESAT-6 fusion protein of M.tuberculosis in mice. Zhong Guo Fang Lao Za Zhi 2012; 3: 19-23.
58. Liu YL, Liu ZP Observing the Effect of Alltride Enteric-Coated Soft Capsules Combined With Anti-tuberculosis Medicine on Pulmonary Tuberculosis. Zhong Guo Yi Liao Qian Yan 2008,;3: 23-5.
59. Wang SY, Wang XL, Liu MM Experimental study of effects of Chinese bulbul extracts againsting Mycobacterium Tuberculosis in vitro. Shi Zhen Guo Yi Guo Yao 2011; 22:2965-6.
60. Kuang TJ, Dong M, Song P., et al In vitro antibacterial effects of berberine on mycobacterium tuberculosis. Zhong Guo Zhong Yao Za Zhi 2001; 26: 867-8.
61. Chen CS, Liang Y. Analysis of the potency of matrine in the inhibition of mycobacteritum tuberculosis. Shou Du Yi Yao 2006; 13:44
62. Gao MQ, Zhu LZ, Yuan SL The observation of short-term efficacy and safety of Chinese herbal medicine Feitai Capsule adjunctive therapy for retreatment of pulmonary tuberculosis. Zhong Hua Jie He He Hu Xi Za Zhi 2006; 29: 134-6.
63. Hao XP, Yang QF Observation of clinical effect of Shenling Baizhu Powder on treatment of gastrointestinal side effect of antituberculosis drugs. Xin Zhong Yi 2003; 35: 34-5.
64. Zhang LH, Ma XQ; Clinical Study of drug-resistant pulmonary tuberculosis treated by combination of anti-tuberculosis chemicals and Compound Astragalus Capsule. Lin Chuang Fei Ke Za Zhi 2005; 10:665-6.
65. Li G. Research of effects on anti-pulmonary tuberculosis of anti tuberculosis capsule in vitro and in vivo. Zhong Guo Shi Yong Yi Yao, 2010; 5: 5-7.